Genovis Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Genovis
Access all reports
Segment Data
Access more data
Net sales by
Product category
Enzyme
Antibodies
Expenses by
Financials
Genovis AB designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company primarily provides site-specific polymerases, glycanases, antibodies, glycoengineered proteins, and other biopharmaceutical tools. It offers site-specific ADAMTS5 inhibitor; recombinant elastase with or without carbonyl-sulfonate glycosylation; recombinant neutrophil collagenase; recombinant rhinovirus 2C protease with 0 to 7 N-linked glycans; AA47G1; Nedd4 binding protein 2/Nedd4L RFP fusion protein; and monomeric red fluorescent protein variants. The company also provides antibodies, including renin activity assays; renin activity assay reagents; chymase activity assays; chymase activity assay reagents; as well as plasma renin activity tests. In addition, it offers GlycoSMART panels for deglycosylating individual glycoproteins for analysts at pharmaceutical and biotechnology companies engaged in glycoprotein production and analysis. The company sells its products through distributors in Sweden and internationally.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
GENO
Country
🇸🇪 Sweden